{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:29:42Z","timestamp":1750872582517},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,4]]},"DOI":"10.7759\/cureus.39934","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T11:14:35Z","timestamp":1685877275000},"source":"Crossref","is-referenced-by-count":2,"title":["Estimation of Value-Based Price for 48 High-Technology Medical Devices"],"prefix":"10.7759","author":[{"given":"Giulia","family":"Hyeraci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Trippoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melania","family":"Rivano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Messori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39434.500185.25","article-title":"Value based pricing for NHS drugs: an opportunity not to be missed?","volume":"336","author":"Claxton K","year":"2008","unstructured":"Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ. 2008, 336:251-254. 10.1136\/bmj.39434.500185.25","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.11.006","article-title":"Implementation of value-based pricing for medicines","volume":"42","author":"Jommi C","year":"2020","unstructured":"Jommi C, Armeni P, Costa F, Bertolani A, Otto M. Implementation of value-based pricing for medicines. Clin Ther. 2020, 42:15-24. 10.1016\/j.clinthera.2019.11.006","journal-title":"Clin Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4871","article-title":"Value-based pricing for drugs: theme and variations","volume":"319","author":"Kaltenboeck A","year":"2018","unstructured":"Kaltenboeck A, Bach PB. Value-based pricing for drugs: theme and variations. JAMA. 2018, 319:2165-2166. 10.1001\/jama.2018.4871","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0567-4","article-title":"Value-based pricing: L'Enfant terrible?","volume":"36","author":"Garner S","year":"2018","unstructured":"Garner S, Rintoul A, Hill SR. Value-based pricing: L'Enfant terrible?. PharmacoEconomics. 2018, 36:5-6. 10.1007\/s40273-017-0567-4","journal-title":"PharmacoEconomics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320000264","article-title":"Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan","volume":"36","author":"Shiroiwa T","year":"2020","unstructured":"Shiroiwa T. Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan. Int J Technol Assess Health Care. 2020, 36:270-276. 10.1017\/S0266462320000264","journal-title":"Int J Technol Assess Health Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"Bell CM","year":"2006","unstructured":"Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, Neumann PJ. Bias in published cost effectiveness studies: systematic review. BMJ. 2006, 332:699-703. 10.1136\/bmj.38737.607558.80","journal-title":"BMJ"},{"key":"ref7","article-title":"WHO Guideline on Country Pharmaceutical Pricing Policies, Second Edition","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies, Second Edition. World Health Organization, Geneva; 2020."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2019.11.008","article-title":"International experience in therapeutic value and value-based pricing: a rapid review of the literature","volume":"23","author":"Prieto-Pinto L","year":"2020","unstructured":"Prieto-Pinto L, Garz\u00f3n-Orjuela N, Lasalvia P, Casta\u00f1eda-Cardona C, Rosselli D. International experience in therapeutic value and value-based pricing: a rapid review of the literature. Value Health Reg Issues. 2020, 23:37-48. 10.1016\/j.vhri.2019.11.008","journal-title":"Value Health Reg Issues"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-003204","article-title":"Defining innovativeness of high-technology medical devices in an Italian region","volume":"30","author":"Messori A","year":"2023","unstructured":"Messori A, Trippoli S, Bartoli L, Marinai C. Defining innovativeness of high-technology medical devices in an Italian region. Eur J Hosp Pharm. 2023, 30:e10. 10.1136\/ejhpharm-2021-003204","journal-title":"Eur J Hosp Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.47176\/mjiri.35.134","article-title":"Value-based procurement for medical devices: a scoping review","volume":"35","author":"Rahmani K","year":"2021","unstructured":"Rahmani K, Karimi S, Rezayatmand R, Raeisi AR. Value-based procurement for medical devices: a scoping review. Med J Islam Repub Iran. 2021, 35:134. 10.47176\/mjiri.35.134","journal-title":"Med J Islam Repub Iran"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23092","article-title":"Relationship between price and diagnosis-related group tariff for medical devices assessed by a regional health technology assessment committee","volume":"14","author":"Trippoli S","year":"2022","unstructured":"Trippoli S, Messori A, Borselli G, Autieri F, Mamone D, Marinai C. Relationship between price and diagnosis-related group tariff for medical devices assessed by a regional health technology assessment committee. Cureus. 2022, 14:e23092. 10.7759\/cureus.23092","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24695","article-title":"Estimation of value-based price for five high-technology medical devices approved by a regional health technology assessment committee in Italy","volume":"14","author":"Messori A","year":"2022","unstructured":"Messori A, Trippoli S. Estimation of value-based price for five high-technology medical devices approved by a regional health technology assessment committee in Italy. Cureus. 2022, 14:e24695. 10.7759\/cureus.24695","journal-title":"Cureus"},{"key":"ref13","unstructured":"Regione Toscana. Prodotti HTA. (2023). Accessed. April 29, 2023: https:\/\/www.regione.toscana.it\/-\/prodotti-hta."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2021.10.009","article-title":"Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France","volume":"80","author":"Allou A","year":"2022","unstructured":"Allou A, Baschet L, Sabourin C, Montalscot G, Lorgis L, Iriart X. Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France. J Cardiol. 2022, 80:72-79. 10.1016\/j.jjcc.2021.10.009","journal-title":"J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0898-x","article-title":"An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany","volume":"18","author":"Borisenko O","year":"2018","unstructured":"Borisenko O, M\u00fcller-Ehmsen J, Lindenfeld J, Rafflenbeul E, Hamm C. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany. BMC Cardiovasc Disord. 2018, 18:163. 10.1186\/s12872-018-0898-x","journal-title":"BMC Cardiovasc Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.11.014","article-title":"A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: a United Kingdom perspective","volume":"41","author":"Lim HS","year":"2022","unstructured":"Lim HS, Shaw S, Carter AW, Jayawardana S, Mossialos E, Mehra MR. A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: a United Kingdom perspective. J Heart Lung Transplant. 2022, 41:174-186. 10.1016\/j.healun.2021.11.014","journal-title":"J Heart Lung Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.07.012","article-title":"Economic evaluation of left ventricular assist devices for patients with end stage heart failure who are ineligible for cardiac transplantation","volume":"33","author":"Chew DS","year":"2017","unstructured":"Chew DS, Manns B, Miller RJ, Sharma N, Exner DV. Economic evaluation of left ventricular assist devices for patients with end stage heart failure who are ineligible for cardiac transplantation. Can J Cardiol. 2017, 33:1283-1291. 10.1016\/j.cjca.2017.07.012","journal-title":"Can J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1854769","article-title":"An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK","volume":"23","author":"Shore J","year":"2020","unstructured":"Shore J, Russell J, Frankenstein L, Candolfi P, Green M. An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK. J Med Econ. 2020, 23:1425-1434. 10.1080\/13696998.2020.1854769","journal-title":"J Med Econ"},{"key":"ref19","article-title":"Sutureless Aortic Valve Replacement for Treatment of Severe Aortic Stenosis: A Single Technology Assessment of Perceval Sutureless Aortic Valve","author":"Desser AS","year":"2017","unstructured":"Desser AS, Arentz-Hansen H, Fagerlund BF, Harboe I, Lauvrak V. Sutureless Aortic Valve Replacement for Treatment of Severe Aortic Stenosis: A Single Technology Assessment of Perceval Sutureless Aortic Valve. Norwegian Institute of Public Health, Oslo; 2017."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2018.03.012","article-title":"Cost-effectiveness evaluation of heparin coated versus standard graft for bypass surgery in peripheral artery disease alongside a randomised controlled trial","volume":"56","author":"Villemoes MK","year":"2018","unstructured":"Villemoes MK, Lindholt JS, Houlind KC, et al.. Cost-effectiveness evaluation of heparin coated versus standard graft for bypass surgery in peripheral artery disease alongside a randomised controlled trial. Eur J Vasc Endovasc Surg. 2018, 56:87-93. 10.1016\/j.ejvs.2018.03.012","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcz027","article-title":"Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients","volume":"6","author":"Gallone G","year":"2020","unstructured":"Gallone G, Armeni P, Verheye S, et al.. Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. Eur Heart J Qual Care Clin Outcomes. 2020, 6:32-40. 10.1093\/ehjqcco\/qcz027","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1559600","article-title":"Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients","volume":"22","author":"Goodall G","year":"2019","unstructured":"Goodall G, Lamotte M, Ramos M, Maunoury F, Pejchalova B, de Pouvourville G. Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. J Med Econ. 2019, 22:289-296. 10.1080\/13696998.2018.1559600","journal-title":"J Med Econ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2022.03.034","article-title":"Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients","volume":"357","author":"Mennini FS","year":"2022","unstructured":"Mennini FS, Meucci F, Pesarini G, et al.. Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients. Int J Cardiol. 2022, 357:26-32. 10.1016\/j.ijcard.2022.03.034","journal-title":"Int J Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2021.02.013","article-title":"Cost-effectiveness analysis of the SAPIEN 3 transcatheter aortic valve implant in patients with symptomatic severe aortic stenosis","volume":"75","author":"Pinar E","year":"2022","unstructured":"Pinar E, Garc\u00eda de Lara J, Hurtado J, et al.. Cost-effectiveness analysis of the SAPIEN 3 transcatheter aortic valve implant in patients with symptomatic severe aortic stenosis. Rev Esp Cardiol (Engl Ed). 2022, 75:325-333. 10.1016\/j.rec.2021.02.013","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.003","article-title":"Cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France","volume":"25","author":"Gilard M","year":"2022","unstructured":"Gilard M, Eltchaninoff H, Iung B, et al.. Cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. Value Health. 2022, 25:605-613. 10.1016\/j.jval.2021.10.003","journal-title":"Value Health"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S208107","article-title":"A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients","volume":"11","author":"Tarride JE","year":"2019","unstructured":"Tarride JE, Luong T, Goodall G, Burke N, Blackhouse G. A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients. Clinicoecon Outcomes Res. 2019, 11:477-486. 10.2147\/CEOR.S208107","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S185743","article-title":"Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk","volume":"10","author":"Povero M","year":"2018","unstructured":"Povero M, Miceli A, Pradelli L, Ferrarini M, Pinciroli M, Glauber M. Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk. Clinicoecon Outcomes Res. 2018, 10:733-745. 10.2147\/CEOR.S185743","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2018.03.069","article-title":"Cost-effectiveness of self-expandable transcatheter aortic valves in intermediate-risk patients","volume":"106","author":"Tam DY","year":"2018","unstructured":"Tam DY, Hughes A, Wijeysundera HC, Fremes SE. Cost-effectiveness of self-expandable transcatheter aortic valves in intermediate-risk patients. Ann Thorac Surg. 2018, 106:676-683. 10.1016\/j.athoracsur.2018.03.069","journal-title":"Ann Thorac Surg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1409227","article-title":"Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection","volume":"21","author":"Kay G","year":"2018","unstructured":"Kay G, Eby EL, Brown B, et al.. Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection. J Med Econ. 2018, 21:294-300. 10.1080\/13696998.2017.1409227","journal-title":"J Med Econ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11229","article-title":"Cost-effectiveness of the use of Gold Anchor\u2122 markers in prostate cancer","volume":"12","author":"Lundqvist M","year":"2020","unstructured":"Lundqvist M, Levin L\u00c5. Cost-effectiveness of the use of Gold Anchor\u2122 markers in prostate cancer. Cureus. 2020, 12:e11229. 10.7759\/cureus.11229","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1004","article-title":"Cost-utility analysis of selective internal radiation therapy\u00a0with Y-90 resin microspheres in hepatocellular carcinoma","volume":"17","author":"Muszbek N","year":"2021","unstructured":"Muszbek N, Remak E, Evans R, et al.. Cost-utility analysis of selective internal radiation therapy\u00a0with Y-90 resin microspheres in hepatocellular carcinoma. Future Oncol. 2021, 17:1055-1068. 10.2217\/fon-2020-1004","journal-title":"Future Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.04.018","article-title":"Cost-utility analysis of transarterial radioembolization with Yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma","volume":"43","author":"Zarca K","year":"2021","unstructured":"Zarca K, Mimouni M, Pereira H, Chatellier G, Vilgrain V, Durand-Zaleski I. Cost-utility analysis of transarterial radioembolization with Yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma. Clin Ther. 2021, 43:1201-1212. 10.1016\/j.clinthera.2021.04.018","journal-title":"Clin Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2019.11.009","article-title":"A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma","volume":"3","author":"Ahmed II","year":"2020","unstructured":"Ahmed II, Podbielski DW, Patel V, Falvey H, Murray J, Botteman M, Goeree R. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma. 2020, 3:103-113. 10.1016\/j.ogla.2019.11.009","journal-title":"Ophthalmol Glaucoma"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06862-x","article-title":"Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy","volume":"21","author":"Fea AM","year":"2021","unstructured":"Fea AM, Cattel F, Gandolfi S, Buseghin G, Furneri G, Costagliola C. Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy. BMC Health Serv Res. 2021, 21:824. 10.1186\/s12913-021-06862-x","journal-title":"BMC Health Serv Res"},{"key":"ref35","article-title":"Retinal prosthesis system for advanced retinitis pigmentosa: a health technology assessment update","volume":"17","author":"Health Quality Ontario","year":"2017","unstructured":"Health Quality Ontario. Retinal prosthesis system for advanced retinitis pigmentosa: a health technology assessment update. Ont Health Technol Assess Ser. 2017, 17:1-62.","journal-title":"Ont Health Technol Assess Ser"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14745","article-title":"Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: a Markov-model","volume":"99","author":"Pesonen M","year":"2021","unstructured":"Pesonen M, Kankaanp\u00e4\u00e4 E, Vottonen P. Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: a Markov-model. Acta Ophthalmol. 2021, 99:e1146-e1153. 10.1111\/aos.14745","journal-title":"Acta Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3804-4","article-title":"Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN\u00ae) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies","volume":"19","author":"Pochopien M","year":"2019","unstructured":"Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aball\u00e9a S. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN\u00ae) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. BMC Health Serv Res. 2019, 19:22. 10.1186\/s12913-018-3804-4","journal-title":"BMC Health Serv Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312765","article-title":"Dexamethasone implant for non-infectious uveitis: is it cost-effective?","volume":"103","author":"Squires H","year":"2019","unstructured":"Squires H, Bermejo I, Poku EN, et al.. Dexamethasone implant for non-infectious uveitis: is it cost-effective?. Br J Ophthalmol. 2019, 103:1639-1644. 10.1136\/bjophthalmol-2018-312765","journal-title":"Br J Ophthalmol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.100B4.BJJ-2017-0968.R1","article-title":"Patients with unilateral transfemoral amputation treated with a percutaneous osseointegrated prosthesis: a cost-effectiveness analysis","volume":"100-B","author":"Hansson E","year":"2018","unstructured":"Hansson E, Hagberg K, Cawson M, Brodtkorb TH. Patients with unilateral transfemoral amputation treated with a percutaneous osseointegrated prosthesis: a cost-effectiveness analysis. Bone Joint J. 2018, 100-B:527-534. 10.1302\/0301-620X.100B4.BJJ-2017-0968.R1","journal-title":"Bone Joint J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-018-4065-x","article-title":"Comparative cost-effectiveness analysis of the subacromial spacer for irreparable and massive rotator cuff tears","volume":"43","author":"Castagna A","year":"2019","unstructured":"Castagna A, Garofalo R, Maman E, Gray AC, Brooks EA. Comparative cost-effectiveness analysis of the subacromial spacer for irreparable and massive rotator cuff tears. Int Orthop. 2019, 43:395-403. 10.1007\/s00264-018-4065-x","journal-title":"Int Orthop"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.102B4.BJJ-2018-1580.R3","article-title":"Patellofemoral arthroplasty is cheaper and more effective in the short term than total knee arthroplasty for isolated patellofemoral osteoarthritis: cost-effectiveness analysis based on a randomized trial","volume":"102-B","author":"Fredborg C","year":"2020","unstructured":"Fredborg C, Odgaard A, S\u00f8rensen J. Patellofemoral arthroplasty is cheaper and more effective in the short term than total knee arthroplasty for isolated patellofemoral osteoarthritis: cost-effectiveness analysis based on a randomized trial. Bone Joint J. 2020, 102-B:449-457. 10.1302\/0301-620X.102B4.BJJ-2018-1580.R3","journal-title":"Bone Joint J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00236-5","article-title":"Minimally invasive sacroiliac joint fusion with triangular titanium implants: cost-utility analysis from NHS perspective","volume":"5","author":"Blissett DB","year":"2021","unstructured":"Blissett DB, Blissett RS, Ede MP, Stott PM, Cher DJ, Reckling WC. Minimally invasive sacroiliac joint fusion with triangular titanium implants: cost-utility analysis from NHS perspective. Pharmacoecon Open. 2021, 5:197-209. 10.1007\/s41669-020-00236-5","journal-title":"Pharmacoecon Open"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.otsr.2020.03.012","article-title":"Do custom 3D-printed revision acetabular implants provide enough value to justify the additional costs? The health-economic comparison of a new porous 3D-printed hip implant for revision arthroplasty of Paprosky type 3B acetabular defects and its closest alternative","volume":"107","author":"Tack P","year":"2021","unstructured":"Tack P, Victor J, Gemmel P, Annemans L. Do custom 3D-printed revision acetabular implants provide enough value to justify the additional costs? The health-economic comparison of a new porous 3D-printed hip implant for revision arthroplasty of Paprosky type 3B acetabular defects and its closest alternative. Orthop Traumatol Surg Res. 2021, 107:102600. 10.1016\/j.otsr.2020.03.012","journal-title":"Orthop Traumatol Surg Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003981","article-title":"A multicenter randomized controlled trial comparing safety, efficacy, and cost-effectiveness of the surgisis anal fistula plug versus surgeon's preference for transsphincteric fistula-in-ano: the FIAT trial","volume":"273","author":"Jayne DG","year":"2021","unstructured":"Jayne DG, Scholefield J, Tolan D, et al.. A multicenter randomized controlled trial comparing safety, efficacy, and cost-effectiveness of the surgisis anal fistula plug versus surgeon's preference for transsphincteric fistula-in-ano: the FIAT trial. Ann Surg. 2021, 273:433-441. 10.1097\/SLA.0000000000003981","journal-title":"Ann Surg"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3310\/hta25180","article-title":"Sacral nerve stimulation versus the magnetic sphincter augmentation device for adult faecal incontinence: the SaFaRI RCT","volume":"25","author":"Jayne DG","year":"2021","unstructured":"Jayne DG, Williams AE, Corrigan N, et al.. Sacral nerve stimulation versus the magnetic sphincter augmentation device for adult faecal incontinence: the SaFaRI RCT. Health Technol Assess. 2021, 25:1-96. 10.3310\/hta25180","journal-title":"Health Technol Assess"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23559","article-title":"A cost-utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: a publicly funded health care perspective","volume":"37","author":"Shamout S","year":"2018","unstructured":"Shamout S, Nazha S, Dragomir A, Campeau L. A cost-utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: a publicly funded health care perspective. Neurourol Urodyn. 2018, 37:2195-2203. 10.1002\/nau.23559","journal-title":"Neurourol Urodyn"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01081-y","article-title":"The potential cost-effectiveness of a cell-based bioelectronic implantable device delivering interferon-\u03b21a therapy versus injectable interferon-\u03b21a treatment in relapsing-remitting multiple sclerosis","volume":"40","author":"Visser LA","year":"2022","unstructured":"Visser LA, Folcher M, Delgado Simao C, Gutierrez Arechederra B, Escudero E, Uyl-de Groot CA, Redekop WK. The potential cost-effectiveness of a cell-based bioelectronic implantable device delivering interferon-\u03b21a therapy versus injectable interferon-\u03b21a treatment in relapsing-remitting multiple sclerosis. PharmacoEconomics. 2022, 40:91-108. 10.1007\/s40273-021-01081-y","journal-title":"PharmacoEconomics"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1159\/000497101","article-title":"Clinical and economic benefits of upper airway stimulation for obstructive sleep apnea in a European setting","volume":"98","author":"Pietzsch JB","year":"2019","unstructured":"Pietzsch JB, Richter AK, Randerath W, et al.. Clinical and economic benefits of upper airway stimulation for obstructive sleep apnea in a European setting. Respiration. 2019, 98:38-47. 10.1159\/000497101","journal-title":"Respiration"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00198-8","article-title":"A corticosteroid-eluting sinus implant following endoscopic sinus surgery for chronic rhinosinusitis: a UK-based cost-effectiveness analysis","volume":"4","author":"Javanbakht M","year":"2020","unstructured":"Javanbakht M, Saleh H, Hemami MR, Branagan-Harris M, Boiano M. A corticosteroid-eluting sinus implant following endoscopic sinus surgery for chronic rhinosinusitis: a UK-based cost-effectiveness analysis. Pharmacoecon Open. 2020, 4:679-686. 10.1007\/s41669-020-00198-8","journal-title":"Pharmacoecon Open"},{"key":"ref50","article-title":"Pharmacoeconomic Report: Etonogestrel Extended-Release Subdermal Implant (Nexplanon)","author":"CADTH","year":"2020","unstructured":"CADTH. Pharmacoeconomic Report: Etonogestrel Extended-Release Subdermal Implant (Nexplanon). Canadian Agency for Drugs and Technologies in Health, Ottawa; 2020."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1177\/1129729820921021","article-title":"Endovascular versus surgical creation of arteriovenous fistula in hemodialysis patients: cost-effectiveness and budget impact analyses","volume":"22","author":"Rognoni C","year":"2021","unstructured":"Rognoni C, Tozzi M, Tarricone R. Endovascular versus surgical creation of arteriovenous fistula in hemodialysis patients: cost-effectiveness and budget impact analyses. J Vasc Access. 2021, 22:48-57. 10.1177\/1129729820921021","journal-title":"J Vasc Access"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39062","article-title":"Managing tenders in the procurement of advanced medical devices: an original model based on the net monetary benefit combined with three clinical endpoints","volume":"15","author":"Messori A","year":"2023","unstructured":"Messori A, Trippoli S, Fadda V, Romeo MR. Managing tenders in the procurement of advanced medical devices: an original model based on the net monetary benefit combined with three clinical endpoints. Cureus. 2023, 15:e39062. 10.7759\/cureus.39062","journal-title":"Cureus"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00049-7","article-title":"Tenders for the procurement of medical devices: adapting cost-effectiveness rules to the requirements of the European public procurement directive","volume":"54","author":"Messori A","year":"2020","unstructured":"Messori A, Trippoli S, Caccese E, Marinai C. Tenders for the procurement of medical devices: adapting cost-effectiveness rules to the requirements of the European public procurement directive. Ther Innov Regul Sci. 2020, 54:226-231. 10.1007\/s43441-019-00049-7","journal-title":"Ther Innov Regul Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/156681-estimation-of-value-based-price-for-48-high-technology-medical-devices","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:24Z","timestamp":1707509064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/156681-estimation-of-value-based-price-for-48-high-technology-medical-devices"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,4]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.39934","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,4]]}}}